
Luigi Di Serafino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5422697/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Platelet Inhibition with Ticagrelor 60Âmg Versus 90Âmg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial. Cardiovascular Drugs and Therapy, 2023, 37, 1031-1038.	2.6	3
2	ADDED Index or Percentage Diameter of Residual Coronary Stenosis to Risk-Stratify Patients Presenting With STEMI. Cardiovascular Revascularization Medicine, 2022, 34, 92-98.	0.8	4
3	Pathophysiology and mechanisms of Acute Coronary Syndromes: atherothrombosis, immune-inflammation, and beyond. Expert Review of Cardiovascular Therapy, 2022, 20, 351-362.	1.5	4
4	Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the Euro Bifurcation Club registry. Panminerva Medica, 2022, , .	0.8	1
5	May FFRâ€guided PCI save lives?. Catheterization and Cardiovascular Interventions, 2022, 100, 49-50.	1.7	0
6	Predictors of adherence to composite therapy after acute coronary syndromes. Journal of Cardiovascular Medicine, 2021, 22, 645-651.	1.5	3
7	Relationship between peripheral arterial reactive hyperemia and the index of myocardial resistance in patients undergoing invasive coronary angiography. International Journal of Cardiology, 2021, 333, 8-13.	1.7	5
8	Functionally Complete Coronary Revascularisation in Patients Presenting with ST-elevation MI and Multivessel Coronary Artery Disease. Interventional Cardiology Review, 2021, 16, e24.	1.6	0
9	Extent of Cardiac Damage and Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation. Journal of Clinical Medicine, 2021, 10, 4563.	2.4	6
10	Coronary microcirculation and peri-procedural myocardial injury during elective percutaneous coronary intervention. International Journal of Cardiology, 2020, 306, 42-46.	1.7	17
11	Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. Angiology, 2020, 71, 235-241.	1.8	3
12	Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. Journal of Thrombosis and Thrombolysis, 2020, 50, 468-472.	2.1	20
13	Antiplatelet Therapy in Acute Coronary Syndromes. Lights and Shadows of Platelet Function Tests to Guide the Best Therapeutic Approach. Current Vascular Pharmacology, 2020, 18, 262-272.	1.7	13
14	Double-kissing culotte technique for coronary bifurcation stenting. EuroIntervention, 2020, 16, e724-e733.	3.2	13
15	Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry. Angiology, 2019, 70, 257-263.	1.8	21
16	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). American Journal of Cardiology, 2019, 124, 1662-1668.	1.6	20
17	True double bifurcation lesions: new application of the self-expandable Axxess stent and review of literature with dedicated bifurcation devices. Cardiovascular Revascularization Medicine, 2019, 20, 254-260.	0.8	3
18	Comparison of the Effect of Dual-Axis Rotational Coronary Angiography Versus Conventional Coronary Angiography on Frequency of Acute Kidney Injury, X-Ray Exposure Time, and Quantity of Contrast Medium Injected. American Journal of Cardiology, 2018, 121, 1046-1050.	1.6	6

Luigi Di Serafino

#	Article	IF	CITATIONS
19	Macrophage migration inhibitory factor (MIF) is associated with degree of collateralization in patients with totally occluded coronary arteries. International Journal of Cardiology, 2018, 262, 14-19.	1.7	6
20	In-stent fractional flow reserve variations and related optical coherence tomography findings: the FFR–OCT co-registration study. International Journal of Cardiovascular Imaging, 2018, 34, 495-502.	1.5	6
21	Platelet reactivity and coronary microvascular impairment after percutaneous revascularization in stable patients receiving clopidogrel or prasugrel. Atherosclerosis, 2018, 278, 23-28.	0.8	18
22	Diagnostic Performance of Inâ€Procedure Angiographyâ€Derived Quantitative Flow Reserve Compared to Pressureâ€Derived Fractional Flow Reserve: The FAVOR II Europeâ€Japan Study. Journal of the American Heart Association, 2018, 7, .	3.7	240
23	Response to letter to the editor regarding article "Macrophage migration inhibitory factor (MIF) is associated with degree of collateralization in patients with totally occluded coronary arteriesâ€ . International Journal of Cardiology, 2018, 268, 43.	1.7	Ο
24	Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: Role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Longâ€Term Outcome. Journal of Interventional Cardiology, 2017, 30, 5-15.	1.2	8
25	Very late bioresorbable scaffold thrombosis and reoccurrence of dissection two years later chronic total occlusion recanalization of the left anterior descending artery. World Journal of Cardiology, 2017, 9, 710.	1.5	Ο
26	Effects of Prasugrel Versus Clopidogrel on Coronary Microvascular Function in Patients Undergoing Elective PCI. Journal of the American College of Cardiology, 2016, 68, 235-237.	2.8	17
27	FFR prediction model based on conventional quantitative coronary angiography and the amount of myocardium subtended by an intermediate coronary artery stenosis. International Journal of Cardiology, 2016, 223, 340-344.	1.7	10
28	Periprocedural Myocardial Injury and Long-Term Clinical Outcome in Patients Undergoing Percutaneous Coronary Interventions of Coronary Chronic Total Occlusion. Journal of Invasive Cardiology, 2016, 28, 410-414.	0.4	18
29	Response to Letter Regarding Article, "Revascularization Decisions in Patients With Stable Angina and Intermediate Lesions: Results of the International Survey on Interventional Strategy― Circulation: Cardiovascular Interventions, 2015, 8, e002296.	3.9	3
30	Revascularization Decisions in Patients With Stable Angina and Intermediate Lesions. Circulation: Cardiovascular Interventions, 2014, 7, 751-759.	3.9	140
31	Impact of Alpha- and Beta-Adrenergic Receptor Blockers on Fractional Flow Reserve and Index of Microvascular Resistance. Journal of Cardiovascular Translational Research, 2014, 7, 803-809.	2.4	16
32	ACEF and clinical SYNTAX score in the risk stratification of patients with heavily calcified coronary stenosis undergoing rotational atherectomy with stent implantation. Catheterization and Cardiovascular Interventions, 2014, 83, 1067-1073.	1.7	30
33	Potential Additive Effects of Ticagrelor, Ivabradine, and Carvedilol on Sinus Node. Case Reports in Cardiology, 2014, 2014, 1-4.	0.2	4
34	Monocyte–Platelets Aggregates as Cellular Biomarker of Endothelium-Dependent Coronary Vasomotor Dysfunction in Patients with Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2014, 7, 1-8.	2.4	11
35	Prognostic Value of FractionalÂFlowÂReserve. Journal of the American College of Cardiology, 2014, 64, 1641-1654.	2.8	513
36	The Age, Creatinine, and Ejection Fraction Score to Risk Stratify Patients Who Underwent Percutaneous Coronary Intervention of Coronary Chronic Total Occlusion. American Journal of Cardiology, 2014, 114, 1158-1164.	1.6	29

Luigi Di Serafino

#	Article	IF	CITATIONS
37	Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. European Heart Journal, 2014, 35, 2831-2838.	2.2	259
38	Long-term clinical outcome after fractional flow reserve– versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts. American Heart Journal, 2013, 166, 110-118.	2.7	52
39	Quantitative angiography and optical coherence tomography for the functional assessment of nonobstructive coronary stenoses: Comparison with fractional flow reserve. American Heart Journal, 2013, 166, 1010-1018.e1.	2.7	39
40	Intracoronary Enalaprilat to Reduce Microvascular Damage During Percutaneous Coronary Intervention (ProMicro) Study. Journal of the American College of Cardiology, 2013, 61, 615-621.	2.8	53
41	Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with peripheral arterial disease. International Journal of Cardiology, 2013, 167, 2566-2571.	1.7	27
42	Contrast-Induced Nephropathy in Patients Undergoing Primary Percutaneous Coronary Intervention Without Acute Left Ventricular Ejection Fraction Impairment. American Journal of Cardiology, 2013, 111, 684-688.	1.6	34
43	Fractional Flow Reserve–Guided Versus Angiography-Guided Coronary Artery Bypass Graft Surgery. Circulation, 2013, 128, 1405-1411.	1.6	164
44	Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, 604-611.	1.7	13
45	Impact of negative lesion characteristics of chronic total occlusions on procedural outcome and strategy. Acta Cardiologica, 2013, 68, 455-461.	0.9	4
46	Influence of transradial versus transfemoral diagnostic heart catheterisation on peripheral vascular endothelial function. EuroIntervention, 2013, 8, 1252-1258.	3.2	16
47	Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 2012, 10, 2452-2461.	3.8	34
48	EGFR trans-activation by urotensin II receptor is mediated by β-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Research in Cardiology, 2011, 106, 577-589.	5.9	68
49	Rotational atherectomy for the treatment of isolated femoral artery traumatic lesion: a case report. Monaldi Archives for Chest Disease, 2009, 72, .	0.6	о
50	Endovascular repair for isolated iliac artery aneurysms: case report and review of the current literature. Journal of Cardiovascular Medicine, 2009, 10, 861-865.	1.5	4